Date Insider Type Main position Quantity % Market Cap. Importance
17/11/23 Issuer sale

Founder

2,712,529 11.0880%
17/11/23 Issuer sale

See Remarks

14,285 0.0584%
17/11/23 Issuer sale

Chief Financial Officer

125,000 0.5110%
Change 5-day change 1-year change 3-year change Capi.($)
-17.95%-19.50% - - 16.15M
-0.94%-0.71%+45.60%+103.25% 68.52B
-0.74%-5.87%+30.95%+74.66% 62.88B
+3.13%+1.71%-12.50%+390.48% 28.13B
-2.74%-6.31%+26.33%+11.24% 25.56B
-0.54%-5.47%-3.88%-18.31% 24.65B
-1.73%-4.51%+18.60%-19.06% 19.81B
-4.27%+3.07%+211.22%+362.48% 17.69B
-1.37%-4.51%-5.21%+507.43% 14.66B
+1.14%-0.34%+52.38%+163.82% 14.45B
Average -2.60%-1.63%+40.39%+175.11% 30.71B
Weighted average by Cap. -0.80%-1.87%+36.49%+139.06%
Logo Acer Therapeutics Inc.
Acer Therapeutics Inc. is a pharmaceutical company, which is focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. The Company’s product pipeline includes OLPRUVA (sodium phenylbutyrate), ACER-801 (osanetant) and EDSIVO (celiprolol). OLPRUVA (sodium phenylbutyrate) for oral suspension is a formulation of sodium phenylbutyrate powder, for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD). Its ACER-801 (osanetant) is an investigational non-hormonal, neurokinin 3 receptor (NK3R) antagonist for the treatment of asomotor symptoms (VMS), post-traumatic stress disorder (PTSD), and prostate cancer. Its EDSIVO (celiprolol) is a selective adrenergic modulator for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation.
Employees
33
  1. Stock Market
  2. Stocks
  3. ACER Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!